--- title: "Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Increases By 94.9%" type: "News" locale: "en" url: "https://longbridge.com/en/news/296026963.md" description: "Bayer's short interest surged 94.9% to 522,716 shares as of July 31, with a days-to-cover ratio of 0.4. Despite this bearish signal, Wall Street analysts maintain a 'Buy' consensus, citing recent upgrades from Deutsche Bank, Zacks, and DZ Bank. The company recently reported Q2 EPS of $0.29, beating estimates, with revenue at $12.53 billion. Stock remained flat at $13.84 on Friday." datetime: "2026-08-16T15:00:31.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296026963.md) - [en](https://longbridge.com/en/news/296026963.md) - [zh-HK](https://longbridge.com/zh-HK/news/296026963.md) generator: "portal-rs" --- # Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Increases By 94.9% Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) was the target of a significant growth in short interest in July. As of July 31st, there was short interest totaling 522,716 shares, a growth of 94.9% from the July 15th total of 268,144 shares. Based on an average daily volume of 1,354,099 shares, the short-interest ratio is currently 0.4 days. Approximately 0.0% of the company's stock are sold short. ## Wall Street Analysts Forecast Growth - ORIC: Working with Two Pharma Giants, Analysts See +100% Upside BAYRY has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft raised Bayer Aktiengesellschaft from a "hold" rating to a "buy" rating in a research note on Thursday, July 2nd. Jefferies Financial Group raised shares of Bayer Aktiengesellschaft to a "hold" rating in a research report on Friday, May 29th. Zacks Research raised shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Friday, July 10th. Finally, DZ Bank upgraded shares of Bayer Aktiengesellschaft from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 19th. Two research analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, Bayer Aktiengesellschaft presently has an average rating of "Buy". **Read Our Latest Analysis on BAYRY** ## Bayer Aktiengesellschaft Stock Performance - ScottsMiracle-Gro Stock Blooms After Investor Day Optimism Shares of BAYRY stock remained flat at $13.84 during trading hours on Friday. 396,144 shares of the stock were exchanged, compared to its average volume of 990,166. The company has a current ratio of 1.05, a quick ratio of 0.70 and a debt-to-equity ratio of 1.06. The business has a 50 day moving average of $13.03 and a two-hundred day moving average of $12.18. Bayer Aktiengesellschaft has a 52-week low of $7.48 and a 52-week high of $15.23. The firm has a market capitalization of $54.39 billion, a price-to-earnings ratio of -27.14, a PEG ratio of 4.34 and a beta of 0.55. Bayer Aktiengesellschaft (OTCMKTS:BAYRY - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.29 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.23 by $0.06. The company had revenue of $12.53 billion for the quarter, compared to analysts' expectations of $12.31 billion. Bayer Aktiengesellschaft had a negative net margin of 3.80% and a positive return on equity of 17.00%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.200-1.346 EPS. Equities research analysts forecast that Bayer Aktiengesellschaft will post 1.28 EPS for the current year. ## About Bayer Aktiengesellschaft (Get Free Report) Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields. In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women's health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates. ## Featured Stories - Five stocks we like better than Bayer Aktiengesellschaft - Meta and Tesla Are Rebounding From Oversold Levels—Now What? - AMG’s Alternatives Boom Powers Record Growth - Microsoft's Maia 300 Chip Targets NVIDIA's AI Dominance - 3 Unexpected ETFs Crushing the Market This Summer *This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.* Continue following MarketBeat Add MarketBeat as your preferred source on Google to see our latest stories in your feed. Add As Preferred Source ## Should You Invest $1,000 in Bayer Aktiengesellschaft Right Now? Before you consider Bayer Aktiengesellschaft, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bayer Aktiengesellschaft wasn't on the list. While Bayer Aktiengesellschaft currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys. View The Five Stocks Here ### Related Stocks - [BAYRY.US](https://longbridge.com/en/quote/BAYRY.US.md) - [BAYN.DE](https://longbridge.com/en/quote/BAYN.DE.md) - [DB.US](https://longbridge.com/en/quote/DB.US.md) - [DBK.DE](https://longbridge.com/en/quote/DBK.DE.md) - [JEF.US](https://longbridge.com/en/quote/JEF.US.md) - [SMG.US](https://longbridge.com/en/quote/SMG.US.md) - [META.US](https://longbridge.com/en/quote/META.US.md) - [TSLA.US](https://longbridge.com/en/quote/TSLA.US.md) - [AMG.US](https://longbridge.com/en/quote/AMG.US.md) - [MSFT.US](https://longbridge.com/en/quote/MSFT.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [BAYZF.US](https://longbridge.com/en/quote/BAYZF.US.md) - [03KB.DE](https://longbridge.com/en/quote/03KB.DE.md) - [DPB.DE](https://longbridge.com/en/quote/DPB.DE.md) - [MGRE.US](https://longbridge.com/en/quote/MGRE.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Bayer says Japan approves sevabertinib for HER2-mutant NSCLC](https://longbridge.com/en/news/296745277.md) - [MustGrow Receives First Milestone Payment from Bayer AG | MGROF Stock News](https://longbridge.com/en/news/296609006.md) - [BAYN: Strong 2025 results, innovation focus, and €2bn cost savings drive improved financial outlook](https://longbridge.com/en/news/294831947.md) - [Bayer Swings to Net Profit on Smaller Litigation Charges](https://longbridge.com/en/news/294778020.md) - [Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement | BAYRY Stock News](https://longbridge.com/en/news/286570938.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**